/TAK
TAK Stock - Takeda Pharmaceutical Company Limited
Healthcare|Drug Manufacturers - Specialty & GenericNYSE
$14.90+0.47%
+$0.07 (+0.47%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.62
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $16.39
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TAK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$14.75 – $15.05
TARGET (TP)$17.13
STOP LOSS$13.71
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.03
52W High$15.69
52W Low$12.80
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.58T | $4.26T | $4.03T | $3.57T | $3.20T |
| Gross Profit | $3.00T | $2.83T | $2.78T | $2.46T | $2.20T |
| Gross Margin | 65.5% | 66.4% | 69.1% | 69.0% | 68.9% |
| Operating Income | $342.59B | $214.07B | $490.50B | $460.84B | $509.27B |
| Net Income | $107.93B | $144.07B | $317.02B | $230.06B | $376.00B |
| Net Margin | 2.4% | 3.4% | 7.9% | 6.4% | 11.8% |
| EPS | $34.17 | $46.05 | $102.15 | $73.57 | $120.36 |
Company Overview
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$22
Average Target
↑ 47.7% Upside
Now
$20
Low
$22
Average
$24
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 2nd 2025 | Morgan Stanley | Upgrade | Overweight | - |
| March 16th 2023 | BofA Securities | Upgrade | Buy | $20 |
| July 19th 2022 | Cowen | Upgrade | Outperform | $24← $21 |
Earnings History & Surprises
TAKBeat Rate
67%
Last 15 quarters
Avg Surprise
+136.3%
EPS vs Estimate
Beats / Misses
10/4
1 met exactly
Latest EPS
$0.44
Q4 2025
EPS Surprise History
Q1 24
+420.5%
$0.51vs$0.10
Q2 24
-330.5%
$-0.01vs$0.00
Q3 24
+51.4%
$0.56vs$0.37
Q4 24
+12.8%
$0.44vs$0.39
Q1 25
-33.3%
$0.42vs$0.63
Q2 25
No data
Q3 25
+10.6%
$0.52vs$0.47
Q4 25
0.0%
$0.44vs$0.44
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Jan 29, 2026 | $0.55 | — | — | — |
Q4 2025 | Oct 30, 2025 | $0.44 | $0.44 | 0.0% | = MET |
Q3 2025 | Jul 30, 2025 | $0.47 | $0.52 | +10.6% | ✓ BEAT |
Q2 2025 | Jun 25, 2025 | — | $-0.22 | — | — |
Q1 2025 | Jan 30, 2025 | $0.63 | $0.42 | -33.3% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $0.39 | $0.44 | +12.8% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $0.37 | $0.56 | +51.4% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $0.00 | $-0.01 | -330.5% | ✗ MISS |
Q1 2024 | Feb 1, 2024 | $0.10 | $0.51 | +420.5% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $0.10 | $0.50 | +418.1% | ✓ BEAT |
Q3 2023 | Jul 27, 2023 | $0.14 | $0.55 | +287.9% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $0.05 | $0.39 | +672.4% | ✓ BEAT |
Q1 2023 | Feb 2, 2023 | $0.28 | $0.46 | +62.1% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $0.06 | $0.38 | +527.1% | ✓ BEAT |
Q1 2022 | Feb 3, 2022 | $0.22 | $0.54 | +144.9% | ✓ BEAT |
Q2 2021 | May 11, 2021 | — | $0.41 | — | — |
Q4 2020 | Oct 29, 2020 | $103.00 | $0.47 | -99.5% | ✗ MISS |
Q3 2020 | Jul 31, 2020 | $104.00 | $0.57 | -99.5% | ✗ MISS |
Q2 2020 | May 13, 2020 | — | $0.13 | — | — |
Latest News
Takeda Zasocitinib Phase 3 Plaque Psoriasis Studies Meet Primary And Ranked Secondary Endpoints, With PASI 90 And PASI 100 Clear Skin Results By Week 16
📈 PositiveBenzinga•Dec 18, 2025, 08:36 AM
Takeda's FRUZAQLA Approved For Reimbursement By BC Cancer For Metastatic Colorectal Cancer
📈 PositiveBenzinga•Dec 16, 2025, 01:17 PM
Reported Saturday, Protagonist Therapeutics And Takeda Highlight VERIFY And THRIVE Data Showing Long-Term Hematocrit Control And Reduced Therapeutic Phlebotomy In PV At ASH 2025
📈 PositiveBenzinga•Dec 8, 2025, 09:05 AM•Also:
Reported Earlier, Innovent Biologics Announces Closing Of Global Strategic Partnership With Takeda For IBI363 And IBI343, With Option On IBI3001, Including $1.2B Upfront And Up To $11.4B Total Deal Value
📈 PositiveBenzinga•Dec 5, 2025, 07:45 AM•Also: ,
Takeda Completed A 7-year Pivotal Phase 3 TIDES Trial Evaluating Its Dengue Vaccine, Qdenga (TAK-003), Showing A Favorable Benefit And Risk Profile Of Qdenga And That Two-dose Regimen Provides Sustained Protection Against Dengue
📈 PositiveBenzinga•Nov 3, 2025, 12:05 PM
Takeda Pharmaceutical shares are trading lower after the company reported worse-than-expected Q2 financial results and cut its FY25 guidance.
📉 NegativeBenzinga•Oct 30, 2025, 12:47 PM
Takeda Pharmaceutical Co Lowers FY2025 Adj EPS Guidance from $3.36 to $3.25; Lowers FY2025 Sales Guidance from $31.339B to $30.524B
📉 NegativeBenzinga•Oct 30, 2025, 10:45 AM
Takeda Pharmaceutical Q2 Adj. EPS $0.43 Misses $0.44 Estimate, Sales $7.520B Miss $8.080B Estimate
📉 NegativeBenzinga•Oct 30, 2025, 07:17 AM
Takeda's HyHub, HyHub Duo Devices Now Available In US For Patients 17 Years, Older
📈 PositiveBenzinga•Oct 27, 2025, 12:43 PM
Reported Earlier, Takeda And Innovent Biologics Collaborate To Develop, Manufacture And Commercialize IBI363 IBI343 Worldwide Outside Greater China With U.S. Co-Commercialization
📈 PositiveBenzinga•Oct 22, 2025, 07:41 AM•Also:
Reported Earlier, Takeda Expands Global CSR Program To 53.7M Beneficiaries With JPY 4.6B Commitment Across 94 Countries
📈 PositiveBenzinga•Sep 24, 2025, 06:38 AM
Takeda, VELA To Transport Products Between Europe, U.S. Using Sailing Cargo Trimaran
➖ NeutralBenzinga•Sep 16, 2025, 12:16 PM
Takeda Reports Results From FirstLight And RadiantLight Studies Showing Oveporexton Improves Wakefulness Cataplexy Severity And Quality Of Life
📈 PositiveBenzinga•Sep 8, 2025, 07:25 AM
On Friday, FDA Approved Takeda's Supplemental Application For Vonvendi, Expanding The Indication To Include Routine Prophylaxis To Reduce The Frequency Of Bleeding Episodes In Adults With Von Willebrand Disease
📈 PositiveBenzinga•Sep 7, 2025, 04:27 PM
Novavax Receives Milestone Payment From Takeda, Triggered By Approval For Novavax's COVID-19 vaccine Nuvaxovid Intramuscular Injection 1 mL
📈 PositiveBenzinga•Sep 4, 2025, 12:10 PM•Also:
Takeda Canada Announces FRUZAQLATM Will Now Be Reimbursed By RAMQ In Quebec
📈 PositiveBenzinga•Aug 28, 2025, 01:31 PM
Frequently Asked Questions about TAK
What is TAK's current stock price?
Takeda Pharmaceutical Company Limited (TAK) is currently trading at $14.90 per share. The stock has moved +0.47% today.
What is the analyst price target for TAK?
No analyst price targets are currently available for this stock.
What sector is Takeda Pharmaceutical Company Limited in?
Takeda Pharmaceutical Company Limited operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NYSE exchange.
What is TAK's market cap?
Takeda Pharmaceutical Company Limited has a market capitalization of $46.98 billion, making it a large-cap company.
Does TAK pay dividends?
No, Takeda Pharmaceutical Company Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorA
Agilent Technologies, Inc.
$137.24
Mkt Cap: $38.9B
ALC
Alcon Inc.
$79.97
Mkt Cap: $39.6B
BDX
Becton, Dickinson and Company
$195.59
Mkt Cap: $56.3B
CAH
Cardinal Health, Inc.
$202.95
Mkt Cap: $48.2B
EW
Edwards Lifesciences Corporation
$85.66
Mkt Cap: $50.3B
HLN
Haleon plc
$9.90
Mkt Cap: $44.9B
INSM
Insmed Incorporated
$174.84
Mkt Cap: $37.3B
IQV
IQVIA Holdings Inc.
$220.66
Mkt Cap: $37.6B
RMD
ResMed Inc.
$244.94
Mkt Cap: $35.9B
VEEV
Veeva Systems Inc.
$221.86
Mkt Cap: $36.5B
Explore stocks similar to TAK for comparison